Strategies Wealth Advisors LLC Buys New Holdings in Johnson & Johnson $JNJ

Key Points

• Strategies Wealth Advisors LLC acquired a new position in Johnson & Johnson, purchasing 1,818 shares valued at approximately $302,000.
• Johnson & Johnson's quarterly dividend of $1.30, representing an annual yield of 2.9%, is set to be paid on September 9th.
• Analysts have provided mixed ratings for Johnson & Johnson, with a consensus rating of "Moderate Buy" and an average price target of $176.29.

Strategies Wealth Advisors LLC purchased a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,818 shares of the company's stock, valued at approximately $302,000.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC raised its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Hudson Value Partners LLC increased its holdings in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares in the last quarter. Burling Wealth Partners LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $3,908,000. Integrated Wealth Concepts LLC boosted its position in shares of Johnson & Johnson by 6.1% during the fourth quarter. Integrated Wealth Concepts LLC now owns 108,473 shares of the company's stock valued at $15,687,000 after buying an additional 6,247 shares during the last quarter. Finally, Empire Financial Management Company LLC grew its holdings in Johnson & Johnson by 18.0% during the fourth quarter. Empire Financial Management Company LLC now owns 17,882 shares of the company's stock worth $2,586,000 after buying an additional 2,732 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Barclays lifted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. UBS Group increased their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Finally, Citigroup lifted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $178.8990 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $180.61. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock's fifty day moving average price is $163.04 and its two-hundred day moving average price is $159.05. The firm has a market cap of $430.85 billion, a PE ratio of 19.13, a PEG ratio of 2.28 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.